ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO498

Safety and Efficacy of a Novel Compression Hemostatic Device for Vascular Access: A Quality Improvement Study

Session Information

  • Dialysis: Vascular Access
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 803 Dialysis: Vascular Access

Authors

  • Abidian, Mohamed Modar, Emory University School of Medicine, Atlanta, Georgia, United States
  • Broxton-Key, Rodella, Emory Healthcare, Atlanta, Georgia, United States
  • Rawls, Forest, Emory Healthcare, Atlanta, Georgia, United States
  • Niyyar, Vandana Dua, Emory University School of Medicine, Atlanta, Georgia, United States
Background

Arteriovenous fistulas (AVF) and arteriovenous grafts (AVG) are common types of vascular access for chronic hemodialysis (HD) patients that require frequent needle cannulations. Proper cannulation and decannulation techniques are important for achieving hemostasis and preventing complications from bleeding. After decannulation, most protocols require manual pressure at vascular access sites to prevent bleeding. A novel compression device with a simple manual inflation/deflation pump has been developed to achieve post decannulation hemostasis. The purpose of this quality improvement (QI) study was to assess the safety and effectiveness of such a device in our clinical practice.

Methods

Our protocol for using the device is detailed in Figure 1. All patients who had HD with either AVF or AVG and were holding manual pressure for hemostasis were eligible for the study. Efficacy outcome was achieving post decannulation homeostasis within 15 minutes. Safety outcome measures were prolonged bleeding (more than 15 minutes), access thrombosis, and local infection. Patient satisfaction surveys were performed using the Likert scale.

Results

We evaluated 166 HD sessions using the compression device in 28 patients. There were no access infections or thrombosis. Only 1 (0.03%) episode of prolonged bleeding post decannulation in a patient who was on warfarin therapy. Almost all patients preferred the device to manual compressions and the average satisfaction rate was 4.6/5.

Conclusion

This novel device was safe and effective in achieving post-cannulation hemostasis and was preferred to manual compression by patients at our center.

Table 1. Incidence Rate of Complications
No. of patientsTotal No. (average per patient) of HD sessions performed using the deviceNo. of prolonged bleeding >15 min per patientNo. of access thrombosisNo. of local infectionAverage patient satisfaction (1-5)
28166 (5.8 per patient)1 (0.03%)0 (0%)0 (0%)4.6

Figure 1: Instructions

Funding

  • Commercial Support – No financial payment was received by the manufacturing company Sun-Scientific as the device was donated free of cost